{"id":"ceftolozane-tazobactam-injection","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Diarrhea"},{"rate":"3-8","effect":"Nausea"},{"rate":"2-5","effect":"Headache"},{"rate":"2-5","effect":"Vomiting"},{"rate":"2-4","effect":"Fever"},{"rate":"1-3","effect":"Hypersensitivity reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ceftolozane is a fifth-generation cephalosporin that binds to penicillin-binding proteins and disrupts peptidoglycan cross-linking in the bacterial cell wall. Tazobactam is a beta-lactamase inhibitor that protects ceftolozane from degradation by bacterial beta-lactamase enzymes, particularly those produced by Pseudomonas aeruginosa and Enterobacteriaceae. This combination extends the spectrum of activity against multidrug-resistant gram-negative pathogens.","oneSentence":"Ceftolozane inhibits bacterial cell wall synthesis while tazobactam inhibits beta-lactamase enzymes, together providing broad-spectrum coverage against resistant gram-negative bacteria.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:29:52.936Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Complicated urinary tract infections (cUTI) including pyelonephritis"},{"name":"Complicated intra-abdominal infections (cIAI)"},{"name":"Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP)"}]},"trialDetails":[{"nctId":"NCT04673175","phase":"PHASE4","title":"Ceftolozane-Tazobactam for Directed Treatment of Pseudomonas Aeruginosa Bacteremia and Pneumonia in Patients With Hematological Malignancies and Hematopoietic Stem Cell Transplantation","status":"TERMINATED","sponsor":"Weill Medical College of Cornell University","startDate":"2023-01-10","conditions":"Pneumonia, Hematologic Malignancy, Pseudomonas Aeruginosa Infection","enrollment":17},{"nctId":"NCT02070757","phase":"PHASE3","title":"Safety and Efficacy Study of Ceftolozane/Tazobactam to Treat Ventilated Nosocomial Pneumonia (MK-7625A-008)","status":"COMPLETED","sponsor":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2014-09-02","conditions":"Healthcare-Associated Pneumonia, Ventilator-Associated Pneumonia, Lung Diseases","enrollment":726}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Ceftolozane / Tazobactam Injection","genericName":"Ceftolozane / Tazobactam Injection","companyName":"Weill Medical College of Cornell University","companyId":"weill-medical-college-of-cornell-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ceftolozane inhibits bacterial cell wall synthesis while tazobactam inhibits beta-lactamase enzymes, together providing broad-spectrum coverage against resistant gram-negative bacteria. Used for Complicated urinary tract infections (cUTI) including pyelonephritis, Complicated intra-abdominal infections (cIAI), Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}